IntegriChain Executive and Leadership Team

Joshua Halpern, the Co-Founder & Chief Executive Officer at IntegriChain, directs the overarching strategic vision for therapy commercialization and market access. By architecting the long-term roadmap for the ICyte platform, Halpern ensures pharmaceutical manufacturers maintain robust control over government payer contracting and patient services. This leadership role involves constant engagement with the Board to align corporate growth with the evolving needs of specialty medicine. Joshua Halpern drives the expansion of data-driven decision support tools, enabling innovators to digitalize complex market access operations across North American markets. Through rigorous oversight of corporate culture and innovation, the Chief Executive Officer maintains a competitive edge in the health software sector. By prioritizing scalable infrastructure, the Co-Founder & Chief Executive Officer secures the financial and operational health of the organization while fostering deep partnerships with industry stakeholders to improve patient access outcomes.

Matt Heyman, the Chief Financial Officer at IntegriChain, manages the fiscal health and capital allocation strategies necessary for scaling the ICyte platform. Overseeing financial planning, reporting, and risk management, the Chief Financial Officer ensures the organization maintains the resources required to support pharmaceutical innovators. Matt Heyman drives the financial modeling for new market access solutions, providing the data-driven foundation for long-term growth. This leadership role involves close coordination with the executive team to monitor revenue streams from government payer contracting and commercial services. By optimizing internal financial processes, the Chief Financial Officer enhances operational efficiency across all departments. Through rigorous analysis of market trends and investment opportunities, Heyman secures the capital structure needed to sustain innovation in the specialty medicine sector. The Chief Financial Officer maintains strict compliance and fiscal discipline, ensuring the company remains a stable partner for manufacturers navigating complex distribution landscapes.

Sean Downey, the Chief Operating Officer at IntegriChain, executes the operational strategies that power therapy commercialization and patient access services. Overseeing the delivery of consulting expertise and platform implementation, the Chief Operating Officer ensures seamless integration of ICyte into client workflows. Sean Downey drives the optimization of business processes, enabling pharmaceutical manufacturers to streamline their distribution channels and payer contracting. This leadership role involves managing cross-functional teams to deliver high-quality service and support to innovators. By refining operational workflows, the Chief Operating Officer increases the speed and accuracy of market access operations. Through the alignment of internal resources with client needs, Downey supports the company's mission to improve therapy access. The Chief Operating Officer maintains a focus on operational excellence, ensuring that all service delivery models remain scalable and effective in the rapidly evolving landscape of precision medicine and specialty pharmaceutical commercialization.

Brad Burget, the Chief Technology Officer at IntegriChain, engineers the technical architecture of the ICyte platform to support complex therapy commercialization data sets. Overseeing the engineering and product development teams, the Chief Technology Officer ensures the platform remains the premier solution for uniting financial, operational, and commercial data. Brad Burget drives the integration of advanced analytics and cloud-based infrastructure to facilitate seamless market access for pharmaceutical innovators. This role requires constant collaboration with the executive team to translate business requirements into high-performance software applications. By optimizing data processing capabilities, the Chief Technology Officer enables clients to gain actionable insights into distribution channels and patient services. Through the implementation of secure, scalable technology frameworks, Burget supports the company's mission to modernize therapy access. The Chief Technology Officer maintains technical excellence across all global operations, ensuring the platform meets the rigorous demands of precision medicine.